Ilumya Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Ilumya market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historical period can be attributed to factors such as the increasing prevalence of rheumatoid arthritis, rising demand for psoriasis treatments, growing investments in the research and development of new drugs, the expanding burden of psoriasis, and the rising prevalence of immunological disorders.

Future market growth can be attributed to factors such as the rising incidence of plaque psoriasis, increasing demand for tildrakizumab, the growing use of combination therapies, a higher disease burden, and rising healthcare expenditures. Key trends during the forecast period include cutting-edge innovations, the adoption of advanced treatment therapies, product innovation, a growing focus on developing biologics for psoriasis management, and advancements in drug delivery systems.

The growing prevalence of psoriasis is expected to drive the expansion of the ilumya market in the future. Psoriasis is a chronic autoimmune condition that accelerates skin cell production, leading to red, scaly patches. The increasing prevalence of psoriasis is attributed to factors such as improved diagnosis and awareness, environmental influences, genetic predisposition, obesity, and the effects of certain medications and infections. Ilumya plays a crucial role in treating psoriasis by reducing inflammation and slowing the overproduction of skin cells through targeting interleukin-23 (IL-23), thus effectively managing the symptoms of moderate to severe plaque psoriasis. For example, in May 2023, a report from the National Library of Medicine (NLM) predicted an increase in psoriasis incidence and disability-adjusted life years (DALY) in individuals aged 30-39 between 2020 and 2030. Therefore, the rising prevalence of psoriasis is fueling the growth of the ilumya market.

The growing healthcare expenditure is expected to boost the growth of the ilumya market in the coming years. Healthcare expenditure encompasses total spending on medical services, treatments, hospital care, pharmaceuticals, and other healthcare services. The increase in healthcare spending is driven by factors such as an aging population, the rise of chronic diseases, and greater demand for healthcare services. A portion of healthcare expenditure is directed toward advanced treatments such as Ilumya for moderate-to-severe plaque psoriasis, which targets interleukin-23 (IL-23). For instance, a report by the Office for National Statistics in May 2024 indicated that healthcare expenditure rose by 5.6% in nominal terms between 2022 and 2023, compared to a 0.9% increase in 2022. As a result, the growth in healthcare expenditure is driving the growth of the ilumya market.

A key trend in the ilumya market is the development of innovative products, particularly those targeting interleukin-23 (IL-23) for treating moderate-to-severe plaque psoriasis. Moderate-to-severe plaque psoriasis is an advanced form of the condition, where excessive skin cell multiplication leads to thick, scaly patches called plaques. For example, in March 2022, Sun Pharmaceutical Industries Inc., a pharmaceutical company based in India, introduced five data abstracts for ILUMYA (tildrakizumab-asmn) at the 2022 American Academy of Dermatology (AAD) Annual Meeting. These abstracts presented interim real-world data showing the safety and efficacy of ILUMYA in patients with moderate-to-severe plaque psoriasis, highlighting significant improvements in disease activity and quality of life, with no new safety concerns.

The key company operating in the ilumya market is Sun Pharmaceutical Industries Ltd.

North America was the largest region in the ilumya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ilumya report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ilumya market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ilumya is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are suitable candidates for systemic therapy or phototherapy (ultraviolet light treatment). It is a monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in inflammation and the excessive production of skin cells in psoriasis. By inhibiting IL-23, Ilumya helps reduce inflammation and slow the rapid turnover of skin cells, thereby improving symptoms such as plaques, scaling, and redness associated with psoriasis.

The primarily patient demographics of ilumya include pediatric patients and adult patients. Pediatric patients are individuals under 18 who need medical treatment for various health issues. The medication is distributed through a range of channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies. It is used for treating plaque psoriasis, psoriatic arthritis, and other inflammatory conditions.

The ilumya market research report is one of a series of new reports that provides ilumya market statistics, including ilumya industry global market size, regional shares, competitors with a ilumya market share, detailed ilumya market segments, market trends and opportunities, and any further data you may need to thrive in the ilumya industry. This ilumya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ilumya market consists of sales of biologics and biosimilars, dermatology products, and generic pharmaceuticals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.